J&J Takeover Report sends Intra-Cellular Stock Soaring - Barron's
1. Johnson & Johnson is exploring acquiring Intra-Cellular, valued at $10 billion. 2. Intra-Cellular shares rose 22% amid acquisition talks, nearing $116. 3. The biotech focuses on neuropsychiatric conditions and late-stage drug testing. 4. Details about the potential deal could be finalized this week.